Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 2
Submit an article Journal homepage
240
Views
69
CrossRef citations to date
0
Altmetric
Technology Evaluation

Computational prediction of human drug metabolism

Sean Ekins GeneGo, Inc., 500 Renaissance Drive, Suite 106, St. Joseph, MI 49085, USA. [email protected]; [email protected]
,
Sergey Andreyev GeneGo, Inc., 500 Renaissance Drive, Suite 106, St. Joseph, MI 49085, USA. [email protected]; [email protected]
,
Andy Ryabov GeneGo, Inc., 500 Renaissance Drive, Suite 106, St. Joseph, MI 49085, USA. [email protected]; [email protected]
,
Eugene Kirillov GeneGo, Inc., 500 Renaissance Drive, Suite 106, St. Joseph, MI 49085, USA. [email protected]; [email protected]
,
Eugene A Rakhmatulin GeneGo, Inc., 500 Renaissance Drive, Suite 106, St. Joseph, MI 49085, USA. [email protected]; [email protected]
,
Andrej Bugrim GeneGo, Inc., 500 Renaissance Drive, Suite 106, St. Joseph, MI 49085, USA. [email protected]; [email protected]
&
Tatiana Nikolskaya GeneGo, Inc., 500 Renaissance Drive, Suite 106, St. Joseph, MI 49085, USA. [email protected]; [email protected]
 show all
Pages 303-324 | Published online: 16 Aug 2005

Bibliography

  • FDA: Innovation stagnation: challenge and opportunity on the critical path to new medicinal products (2004).
  • WYNALDA MA, WIENKERS LC: Assessment of potential interactions between dopamine agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab. Dispos. (1997) 25:1211–1214.
  • GAO F, JOHNSON DL, EKINS S et al.: Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6 and CYP3A4 in vitro using a single point IC50. J. Biomol. Screen (2002) 7:373–382.
  • LINGET J-M, VIGNARD PD: Automation of metabolic stability studies in microsomes, cytosol and plasma using a 215 Gilson liquid handler. J. Pharm. Biomed. Anal. (1999) 19:893–901.
  • EKINS S, RING BJ, GRACE J, MCROBIE-BELLE DJ, WRIGHTON SA: Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol. Methods (2000) 44:313–324.
  • EDDERSHAW PJ, DICKINS M: Advances in in vitro drug metabolism screening. Pharm. Sci. Technol. Today (1999) 2:13–19.
  • LEACH AR, HANN MM: The in silico world of virtual libraries. Drug Discovery Today (2000) 5:326–336.
  • SHIMADA J, EKINS S, ELKIN C, SHAKNOVICH EI, WERY J-P: Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs. Targets (2002) 1:196–205.
  • EKINS S, DE GROOT M, JONES JP: Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. (2001) 29:936–944.
  • EKINS S, BERBAUM J, HARRISON RK: Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab. Dispos. (2003) 31:1077–1080.
  • BUTINA D, SEGALL MD, FRANKCOMBE K: Predicting ADME properties in silico: methods and models. Drug Disc. Today (2002) 7:S83–S88.
  • EKINS S, WALLER CL, SWAAN PW et al.: Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods (2000) 44(1):251–272.
  • EKINS S, BOULANGER B, SWAAN PW, HUPCEY MAZ: Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput. Aided Mol. Des. (2002) 16:381–401.
  • WESSEL MD, MENTE S: ADME by computer. Ann. Reports in Med. Chem. (2001) 36:257–266.
  • VAN DE WATERBEEMD H, GIFFORD E: ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. (2003) 2:192–204.
  • EKINS S, ROSE JP: In silico ADME/Tox: the state of the art. J. Mol. Graph (2002) 20:305–309.
  • BARRATT MD, RODFORD RA: The computational prediction of toxicity. Curr. Opin. Chem. Biol. (2001) 5:383–388.
  • JOHNSON DE, WOLFGANG GHI: Predicting human safety: screening and computational approaches. Drug Disc. Today (2000) 5:445–454.
  • ERHARDT PW: Drug metabolism data: past and present status. Med. Chem. Res. (1998) 8:400–421.
  • ERHARDT PW: A human drug metabolism database: potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Curr. Drug Metab. (2003) 4:411–422.
  • LANGOWSKI J, LONG A: Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Del. Rev. (2002) 54:407–415.
  • NELSON DR: Introductory remarks on human CYPs. Drug Metab. Rev. (2002) 34:1–5.
  • WILLIAMS JA, HYLAND R, JONES BC et al.: Drug-drug interactions for UDPglucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (auci/auc) ratios. Drug Metab. Dispos. (2004) 32(11):1201–1208.
  • EKINS S: Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discovery Today (2004)
  • LEWIS DFV: Cytochromes P450. Taylor ’ Francis, Bristol, UK (1996).
  • VANDENBRANDEN M, WRIGHTON SA, EKINS S et al.: Alterations in the catalytic activities of drugmetabolizing enzymes in cultures of human liver slices. Drug Metab. Dispos. (1998) 26:1063–1068.
  • EKINS S, MAENPAA J, WRIGHTON SA: In vitro metabolism: subcellular fractions. In: Handbook of drug metabolism. TF Woolf (Ed.), Marcel Dekker, New York, USA (1999):363–399.
  • TUKEY RH, STRASSBURG CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Ann. Rev. Pharmacol. Toxicol. (2000) 40:581–616.
  • HANSCH C: Quantitative relationships between lipophilic character and drug metabolism. Drug Metab. Rev.s (1972) 1:1–14.
  • HANSCH C: The QSAR paradigm in the design of less toxic molecules. Drug Metabolism Reviews (1984) 15:1279–1294.
  • HANSCH C, LIEN EJ, HELMER F: Structure-activity correlations in the metabolism of drugs. Arch. Biochem. Biophys. (1968) 128:319–330.
  • HANSCH C, ZHANG L: Quantitative structure-activity relationships of cytochrome P-450. Drug Metab. Rev. (1993) 25:1–48.
  • AUSTEL VAK E: Absorption, distribution, and metabolism of drugs. In: Quantitative structure-activity relationships of drugs. JG Topliss, V Austel, E Kutter (Eds), Academic Press, NY, USA (1983):437–496.
  • NELSON DR, KOYMANS L, KAMATAKI T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics (1996) 6:1–42.
  • MACKENZIE PI, OWENS IS, BURCHELL B et al.: The UDP glycosyltransferase gene superfamily: recommended nomenclature based on evolutionary divergence. Pharmacogenetics (1997) 7:255–269.
  • LEWIS DFV: Quantitative structure activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). Drug Metab. Rev. (1997) 29:589–650.
  • LEWIS DFV: On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem. Pharmacol. (2000) 60:293–306.
  • LEWIS DFV: Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology (2000) 144:197–203.
  • LEWIS DFV, EDDERSHAW PJ, DICKINS M, TARBIT MH, GOLDFARB PS: Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem. Biol. Interact. (1998) 115:175–199.
  • LEWIS DFV, EDDERSHAW PJ, DICKINS M, TARBIT MH, GOLDFARB PS: Erratum to Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem. Biol. Interact. (1999) 117:187.
  • LEWIS DF, JACOBS MN, DICKINS M: Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Disc. Today (2004) 9(12):530–537.
  • FUHR U, STROBL G, MANAUT F et al.: Quinolone antibacterial agents: relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2. Molecular Pharmacology (1993) 43:191–199.
  • JONES JP, HE M, TRAGER WF, RETTIE AE: Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab. Dispos. (1996) 24:1–6.
  • WALLER CL, EVANS MV, MCKINNEY JD: Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. Drug Metab. Dispos. (1996) 24:203–210.
  • EKINS S, SWAAN PW: Computational models for enzymes, transporters, channels and receptors relevant to ADME/Tox. Rev. Comp. Chem. (2004) 20:333–415.
  • DE GROOT MJ, EKINS S: Pharmacophore modeling of cytochromes P450. Adv. Drug Del. Rev. (2002) 54:367–383.
  • EKINS S, VANDENBRANDEN M, RING BJ, WRIGHTON SA: Examination of purported probes of human CYP2B6. Pharmacogenetics (1997) 7:165–179.
  • EKINS S, VANDENBRANDEN M, RING BJ et al.: Further characterization of the expression and catalytic activity of human CYP2B6. J. Pharmacol. Exp. Ther. (1998) 286:1253–1259.
  • EKINS S, BRAVI G, RING BJ et al.: Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J. Pharmcol. Exp. Ther. (1999) 288:21–29.
  • EKINS S, BRAVI G, WIKEL JH, WRIGHTON SA: Three dimensional quantitative structure activty relationship (3D-QSAR) analysis of CYP3A4 substrates. J. Pharmacol. Exp. Ther. (1999) 291:424–433.
  • EKINS S, BRAVI G, BINKLEY S et al.: Three and four dimensional-quantitative structure activity relationship (3D/4DQSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics (1999) 9:477–489.
  • EKINS S, BRAVI G, BINKLEY S et al.: Three and four dimensional-quantitative structure activity relationship analyses of CYP3A4 inhibitors. J. Pharmacol. Exp. Ther. (1999) 290:429–438.
  • EKINS S, BRAVI G, BINKLEY S et al.: Three and four dimensional-quantitative structure activity relationship (3D/4DQSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos. (2000) 28:994–1002.
  • SNYDER R, SANGAR R, WANG J, EKINS S: Three dimensional quantitative structure activity relationship for CYP2D6 substrates. Quant. Struct. Act. Relationship (2002) 21:357–368.
  • EKINS S, STRESSER DM, WILLIAMS JA: In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol. Sci. (2003) 24:191–196.
  • EKINS S, WRIGHTON SA: Application of in silico approaches to predicting drug- drug interactions: A commentary. J. Pharm. Toxicol. Methods (2001) 44:1–5.
  • ASIKAINEN A, TARHANEN J, POSO A et al.: Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol. In Vitro (2003) 17(4):449–455.
  • FUHR U, STROBL G, MANAUT F et al.: Quinolone antibacterial agents: relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2. Mol. Pharmacol. (1993) 43:191–199.
  • WANG Q, HALPERT JR: Combined three-dimensional quantitative structure—activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab. Dispos. (2002) 30:86–95.
  • AFZELIUS L, ZAMORA I, RIDDERSTROM M et al.: Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three dimensional quantitative structure activity relationship analysis. Mol. Pharmacol. (2001) 59:909–919.
  • EKINS S, WRIGHTON SA: The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. (1999) 31:719–754.
  • EKINS S, RING BJ, BINKLEY SN, HALL SD, WRIGHTON SA: Autoactivation and activation of cytochrome P450s. Int. J. Clin. Pharmacol. Ther. (1998) 36:642–651.
  • WRIGHTON SA, SCHUETZ EG, THUMMEL KE et al.: The human CYP3A subfamily: practical considerations. Drug Metab. Rev. (2000) 32:339–361.
  • HARLOW GR, HALPERT JR: Alaninescanning mutagenesis of a putative substrate recognition site in human cytochrome P4503A4. J. Biol. Chem. (1997) 272:5396–5402.
  • DOMANSKI TL, LIU J, HARLOW GR, HALPERT JR: Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and a-napthoflavone stimulation. Arch. Biochem. Biophys. (1998) 350:223–232.
  • DOMANSKI TL, HE Y-A, HARLOWGR, HALPERT JR: Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. J. Pharmacol. Exp. Ther. (2000) 293:585–591.
  • XUE L, WANG HF, WANG Q et al.: Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B1 oxidation. Chem. Res. Toxicol. (2001) 14:483–491.
  • HE YA, HE YQ, SZKLARZ GD, HALPERT JR: Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. Biochemistry (1997) 36:8831–8839.
  • EKINS S, RING BJ, BINKLEY SN, HALL SD, WRIGHTON SA: Autoactivation and activation of cytochrome P450s. Int. J. Clin. Pharmacol. Ther. (1998) 36:642–651.
  • EGNELL AC, HOUSTON JB, BOYER CS: Predictive models of CYP3A4 heteroactivation: in vitro—in vivo scaling and pharmacophore modelling. J. Pharmacol. Exp. Ther. (2004).
  • EGNELL AC, ERIKSSON C, ALBERTSON N, HOUSTON B, BOYER S: Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J. Pharmacol. Exp. Ther. (2003) 307(3):878–887.
  • COSME J, JOHNSON EF: Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J. Biol. Chem. (2000) 275:2545–2553.
  • WILLIAMS PA, COSME J, WARD A et al. : Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature (2003) 424:464–468.
  • WILLIAMS PA, COSME J, SRIDHAR V, JOHNSON EF, MCREE DE: Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell (2000) 5:121–131.
  • WILLIAMS PA, COSME J, VINKOVIC DM et al.: Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science (2004) 305(5684):683–686.
  • YANO JK, WESTER MR, SCHOCH GA et al.: The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J. Biol. Chem. (2004) 279(37):38091–38094.
  • KOYMANS LMH, VERMEULEN NPE, BAARSLAG A, DONNE-OP DEN, KELDER GM: A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J. Comp. Aided Mol. Des. (1993) 7:281–289.
  • MODI S, PAINE MJ, SUTCLIFFE MJ et al.: A model for human cytochrome P4502D6 based on homology modeling and NMR studies of substrate binding. Biochemistry (1996) 35:4540–4550.
  • LEWIS DFV, LAKE BG, DICKINS M et al.: Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica (1999) 29:361–393.
  • SZKLARZ GD, HALPERT JR: Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci. (1997) 61:2507–2520.
  • SZKLARZ GD, HALPERT JR: Molecular modeling of cytochrome P4503A4. J. Comp. Aided Mol. Des. (1997) 11:265–272.
  • SZKLARZ GD, GRAHAM SE, PAULSEN MD: Molecular modeling of mammalian cytochromes P450: application to study enzyme function. Vitam. Horm. (2000) 58:53–87.
  • LEWIS DFV, EDDERSHAW PJ, GOLDFARB PS, TARBIT MH: Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica (1997) 27:319–340.
  • LEWIS DFV, EDDERSHAW PJ, GOLDFARB PS, TARBIT MH: Molecular modelling of CYP3A4 from an alignment with CYP102: identifcation of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica (1996) 10:1067–1086.
  • LEWIS DFV, DICKINS M, WEAVER RJ et al.: Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica (1998) 28:235–268.
  • LEWIS DFV: Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica (1995) 25:333–366.
  • WISEMAN H, LEWIS DFV: The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme substrate interactions: potential importance to its proposed anti-carcingenic/ carcinogenic actions. Carcinogenesis (1996) 17:1357–1360.
  • BARHELT C, SCHMID RD, PLEISS J: Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking. J. Mol. Model. (2002) 8:327–335.
  • DE GROOT MJ, ALEX AA, JONES BC: Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J. Med. Chem. (2002) 45:1983–1993.
  • DE GROOT MJ, ACKLAND MJ, HORNE VA, ALEX AA, JONES BC: Novel approach to predicting P450- mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. (1999) 42:1515–1524.
  • DE GROOT MJ, ACKLAND MJ, HORNE VA, ALEX AA, JONES BC: A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. (1999) 42:4062–4070.
  • ETHELL BT, EKINS S, WANG J, BURCHELL B: Quantitative structure—activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab. Dispos. (2002) 30:734–738.
  • SMITH PA, SORICH M, MCKINNON R, MINERS JO: QSAR and pharmacophore modelling approaches for the prediction of UDPglucuronosyltransferase substrate selectivity and binding. XIVth World congress of Pharmacology. San Francisco, CA, USA (2002). [poster].
  • SMITH PA, SORICH MJ, MCKINNON RA, MINERS JO: Pharmacophore and quantitative structure—activity relationship modeling: complementary approaches for the rationalization and prediction of UDPglucuronosyltransferase 1A4 substrate selectivity. J. Med. Chem. (2003) 46:1617–1626.
  • SORICH M, SMITH PA, MCKINNON RA, MINERS JO: Pharmacophore and quantitative structure activity relationship modelling of UDPglucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics (2002) 12:635–645.
  • SMITH PA, SORICH MJ, MCKINNON RA, MINERS JO: In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity. Clin. Exp. Pharmacol. Physiol. (2003) 30(11):836–840.
  • SORICH MJ, MINERS JO, MCKINNON RA, SMITH PA: Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol. Pharmacol. (2004) 65(2):301–308.
  • SORICH MJ, MCKINNON RA, MINERS JO, WINKLER DA, SMITH PA: Rapid prediction of chemical metabolism by human UDPglucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J. Med. Chem. (2004) 47(21):5311–5317.
  • DAJANI R, CLEASBY A, NEU M et al.: X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. J. Biol. Chem. (1999) 53:37862–37868.
  • GAMAGE NU, DUGGLEBY RG, BARNETT AC et al.: Structure of a human carcinogen-converting enzyme, SULT1A1. J. Biol. Chem. (2003) 278:7655–7662.
  • BALAKIN KV, EKINS S, BUGRIM A et al.: Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab. Dispos. (2004) 32:1183–1189.
  • BALAKIN KV, EKINS S, BUGRIM A et al.: Quantitative structure-metabolism relationship modeling of the metabolic N-dealkylation rates. Drug Metab. Dispos. (2004) 32:1111–1120.
  • KOROLEV D, BALAKIN KV, NIKOLSKY Y et al.: Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem. (2003) 46:3631–3643.
  • BUGRIM A, NIKOLSKAYA T, NIKOLSKY Y: Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Disc. Today (2004) 9:127–135.
  • SHEN M, XIAO Y, GOLBRAIKH A, GOMBAR VK, TROPSHA A: Development and validation of k-nearest neighbour QSPR models of metabolic stability of drug candidates. J. Med. Chem. (2003) 46:3013–3020.
  • BENNETT KP, EMBRECHTS MJ: An optimization perspective on kernel partial least squares regression. In: Advances in learning theory; methods, models and applications. JAK Suykens et al. (Eds), IOS Press, Amsterdam, The Netherlands (2003):227–250.
  • CHRISTIANINI N, SHAWE-TAYLOR J: Support vector machines and other kernelbased learning methods. Cambridge University Press, Cambridge, MA, USA (2000).
  • ROSIPAL R, TREJO LJ: Kernel partial least squares regression in reproducing kernel hilbert space. J. Machine Learning Research (2001) 2:97–123.
  • ZERNOV VV, BALAKIN KV, IVASHCHENKO AA, SAVCHUK NP, PLETNEV IV: Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. J. Chem. Inf. Comp. Sci. (2003) 43:2048–2056.
  • WARMUTH MK, LIAO J, RATSCH G et al.: Active learning with support vector machines in the drug discovery process. J. Chem. Inf. Comp. Sci. (2003) 43:667–673.
  • TAKAOKA Y, ENDO Y, YAMANOBE S et al.: Development of a method for evaluating drug-likeness and ease of synthesis using a data set in which compounds are assigned scores based on chemistsȁ intuition. J. Chem. Inf. Comp. Sci. (2003) 43(4):1269–1275.
  • LIND P, MALTSEVA T: Support vector machines for the estimation of aqueous solubility. J. Chem. Inf. Comp. Sci. (2003) 43:1855–1859.
  • BRENEMAN C, SUNDLING C, SUKUMAR N et al.: New developments in PEST shape/property hybrid descriptors. J. Comp. Aided Mol. Des. (2003) 17:231–240.
  • JONES JP, MYSINGER M, KORZEKWA KR: Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen abstraction. Drug Metab. Dispos. (2002) 30:7–12.
  • JONES JP, KORZEKWA KR: Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. (Ed.) Academic Press, Inc., New York, USA (1996):326–335.
  • SINGH SB, SHEN LQ, WALKER MJ, SHERIDAN RP: A model for likely sites of CYP3A4-mediated metabolism on drug-like molecules. J. Med. Chem. (2003) 46:1330–1336.
  • CSANADY GA, LAIB JG: Metabolic transformation of halogenated and other alkenes- a theoretical approach. Estimation of metabolic reactivities for in vivo conditions. Toxicology (1995) 75:217–223.
  • YIN H, ANDERS MW, KORZEKWA KR et al.: Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proc. Natl. Acad. Sci. USA (1995) 92:11076–11080.
  • KORZEKWA K, EWING TJ, KOCHER JP, CARLSON TJ: Models for cytochrome P450-mediated metabolism. In: Pharmaceutical Profiling in Drug Discovery for Lead Selection. RT Borchardt et al. (Eds), AAPS Press, AZ USA (2004):69–80.
  • BURSI R, DE GOOYER ME, GROOTENHUIS A et al.: (Q)SAR study on the metabolic stability of steroidal androgens. J. Mol. Graph Model. (2001) 19:552–556.
  • EKINS S, BUGRIM A, NIKOLSKY Y, NIKOLSKAYA T: Systems biology: applications in drug discovery. In: Drug discovery handbook. S Gad (Ed.), Wiley, New York, USA (2005).
  • OLIVER DE, RUBIN DL, STUART JM et al.: Ontology development for a pharmacogenetics knowledge base. Pac. Symp. Biocomp. (2002):88–99.
  • NAKATA K, YUKAWA M, KOMIYAMA N, NAKANO T, KAMINUMA T: A nuclear receptor database that maps pathways to diseases. Genome Infomatics (2002) 13:515–516.
  • YAN Q, SADEE W: Human membrane transporter database: a web-accessible relational database for drug transport studies and pharmacogenomics. AAPS Pharmsci. (2000) 2:E20.
  • SUN LZ, JI ZL, CHEN X, WANG JF, CHEN YZ: ADME-AP: a database of ADME associated proteins. Bioinformatics (2002) 18:1699–1700.
  • ERHARDT PW: A human drug metabolism database: potential roles in the quantitative predictions of drug metabolism and metabolism-related drug—drug interactions. Curr. Drug Metab. (2003) 4:411–422.
  • BOYER S, ZAMORA I: New methods in predictive metabolism. J. Comp. Aided Mol. Des. (2002) 16:403–413.
  • BORODINA Y, SADYM A, FILIMONOV D et al.: Predicting biotransformation potential from molecular structure. J. Chem. Inf. Comp. Sci. (2003) 43(5):1636–1646.
  • BORODINA Y, RUDIK A, FILIMONOV D et al.: A new statistical approach to predicting aromatic hydroxylation sites. Comparison with model-based approaches. J. Chem. Inf. Comp. Sci. (2004) 44(6):1998–2009.
  • SMITH RV, ERHARDT PW, LESLIE SW: Microsomal O-demethylation, N-demethylation and aromatic hydroxylation in the presence of bisulfite and dithiothreitol. Res. Commun. Chem. Path. Pharmacol. (1975) 12:181–184.
  • DARVAS F: MetabolExpert: an expert system for predicting the metabolism of substances. In: QSAR in Environmental Toxicology. KL Kaiser (Ed.), Reidel Co., Dordrecht, Germany (1987):71–81.
  • KLOPMAN G, DIMAYUGA M, TALAFOUS J: META. 1. A program for the evaluation of metabolic transformations of chemicals. J. Chem. Inf. Comp. Sci. (1994) 34:1320–1325.
  • TALAFOUS J, SAYRE LM, MIEYAL JJ, KLOPMAN G: META. 2. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comp. Sci. (1994) 34(6):1326–1333.
  • KLOPMAN G, TU M, TALAFOUS J: META. 3. A genetic algorithm for metabolic transform priorities optimization. J. Chem. Inf. Comp. Sci. (1997) 37:329–334.
  • BUTTON WG, JUDSON PN, LONG A, VESSEY JD: Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J. Chem. Inf. Comp. Sci. (2003) 43:1371–1377.
  • HAWKINS DR: Metabolism databases: their use and value. Med. Chem. Res. (1998) 8:434–443.
  • HOU BK, ELLIS LB, WACKETT LP: Encoding microbial metabolic logic: predicting biodegradation. J. Ind. Microbiol. Biotechnol. (2004) 31(6):261–272.
  • HOU BK, WACKETT LP, ELLIS LB: Microbial pathway prediction: a functional group approach. J. Chem. Inf. Comp. Sci. (2003) 43(3):1051–1057.
  • ELLIS LB, HOU BK, KANG W, WACKETT LP: The University of Minnesota biocatalysis/biodegradation database: post-genomic data mining. Nucleic Acids Res. (2003) 31(1):262–265.
  • MEKENYAN OG, DIMITROV SD, PAVLOV TS, VEITH GD: A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr. Pharm. Des. (2004) 10(11):1273–1293.
  • KESURU GM, MOLNAR L: METAPRINT: a metabolic fingerprint. Application to cassette design for highthroughput ADME screening. J. Chem. Inf. Comp. Sci. (2002) 42:437–444.
  • COOK DL, ATKINS WM: Enhanced detoxication due to distributive catalysis and toxic thresholds: a kinetic analysis. Biochemistry (1997) 36:10802–10806.
  • SO S-S, KARPLUS M: A comparitive study of ligand-receptor complex binding affinity prediction methods based on glycogen phosphorylase inhibitors. J. Comp. Aided Mol. Des. (1999) 13:243–258.
  • EKINS S, DURST GL, STRATFORD RE et al.: Three dimensional quantitative structure-permeability relationship analysis for a series of inhibitors of rhinovirus replication. J. Chem. Inf. Comp. Sci. (2001) 41:1578–1586.
  • EKINS S, MIRNY L, SCHUETZ EG: A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRa and LXRb. Pharm. Res. (2002) 19:1788–1800.
  • EKINS S, SCHUETZ E: The PXR crystal structure: the end of the beginning. TIPS (2002).
  • EKINS S, ERICKSON JA: A pharmacophore for human pregnane-Xreceptor ligands. Drug Metab. Dispos. (2002) 30:96–99.
  • MANKOWSKI DC, EKINS S: Prediction of human drug metabolizing enzyme induction. Curr. Drug Metab. (2003) 4:381–391.
  • WATKINS RE, WISELY GB, MOORE LB et al.: The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science (2001) 292:2329–2333.
  • WATKINS RE, DAVIS-SEARLES PR, LAMBERT MH, REDINBO MR: Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. (2003) 331:815–828.
  • WATKINS RE, MAGLICH JM, MOORE LB et al.: 2.1A crystal structure of human PXR in complex with the St John’s Wort compound hyperforin. Biochemistry (2003) 42:1430–1438.
  • KAUPPI B, JAKOB C, FARNEGARDH M et al.: The threedimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. (2003) 278(25):22748–22754.
  • XU RX, LAMBERT MH, WISELY BB et al.: A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol. Cell (2004) 16(6):919–928.
  • BERTILSSON G, HEIDRICH J, SVENSSON K et al.: Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA (1998) 95(21):12208–12213.
  • BLUMBERG B, SABBAGH W, JR., JUGUILON H et al.: SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. (1998) 12(20):3195–3205.
  • KLIEWER SA, MOORE JT, WADE L et al.: An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell (1998) 92:73–82.
  • BACHMANN K, PATEL H, BATAYNEH Z et al.: PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol. Res. (2004) 50(3):237–246.
  • LEWIS DFV, JACOBS MN, DICKINS M, LAKE BG: Quantitative structure-activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. Toxicology (2002) 176:51–57.
  • HOOD L, GALAS D: The digital code of DNA. Nature (2003) 421(6921):444–448.
  • IDEKER T, LAUFFENBURGER D: Building with a scaffold: emerging strategies for high- to low-level cellular modeling. Trends Biotechnol. (2003) 21(6):255–262.
  • BUGRIM A, NIKOLSKAYA T, NIKOLSKY Y: Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discovery Today (2004) 9:127–135.
  • EKINS S, BERBAUM J, HARRISON RK et al.: Applying computational and in vitro approaches to lead selection. In: Pharmaceutical Profiling in Drug Discovery for Lead Selection. RT Borchardt et al. (Eds). AAPS Press, AZ, USA (2004):361–389.
  • CHENG A, DILLER DJ, DIXON SL et al.: Computation of the physico-chemical properties and data mining of large molecular collections. J. Comput. Chem. (2002) 23:172–183.
  • YOUNG SS, EKINS S, LAMBERT C: So many targets, so many compounds, but so few resources. Curr. Drug Disc. (2002):17–22.
  • YOUNG SS, GOMBAR VK, EMPTAGE MR, CARIELLO NF, LAMBERT C: Mixture deconvolution and analysis of Ames mutagenicity data. Chemo. Intell. Lab. Sys. (2002) 60:5–11.
  • LI AP: A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. (2002) 142:7–23.
  • WILLIAMS DP, PARK BK: Idiosyncratic toxicity: the role of toxicophores and bioactivation. Drug Discov. Today (2003) 8:1044–1050.
  • UETRECHT J: Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov. Today (2003) 8:832–837.
  • EKINS S, NIKOLSKY Y, NIKOLSKAYA T: Techniques: application of systems biology to absorption, distribution, metabolism, excretion, and toxicity. Trends Pharmacol. Sci. (2005) (in press).
  • NIKOLSKY Y, EKINS S, NIKOLSKAYA T, BUGRIM A: A novel method for generation of signature networks as biomarkers from complex high throughput data. Tox. Lett. (2005) (in press).
  • EKINS S, KIRILLOV E, RAKHMATULIN EA, NIKOLSKAYA T: A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab. Dispos. (2005) 33:474–481.
  • UEDA A, HAMADEH HK, WEBB HK et al. : Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. (2002) 61:1–6.
  • WARING JF, GUM R, MORFITT D et al.: Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology (2002) 181–182:537–550.
  • DESTA Z, WARD BA, SOUKHOVA NV, FLOCKHART DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. (2004) 310(3):1062–1075.
  • BEKAII-SAAB TS, PERLOFF MD, WEEMHOFF JL, GREENBLATT DJ, VON MOLTKE LL: Interactions of tamoxifen, N-desmethyltamoxifen and 4- hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm. Drug Dispos. (2004) 25(7):283–289.
  • ERTL P: Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups. J. Chem. Inf. Comp. Sci. (2003) 43:374–380.
  • KORZEKWA KR, KRISHNAMACHARY N, SHOU M et al.: Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry (1998) 37:4137–4147.
  • KIRTON SB, BAXTER CA, SUTCLIFFE MJ: Comparative modelling of the cytochromes P450. Adv. Drug Del. Rev. (2002) 54:385–406.
  • SHERIDAN RP, FEUSTON BP, MAIOROV VN, KEARSLEY SK: Similarity to molecules in the training set is a good discriminator for prediction accuracy in QSAR. J. Chem. Inf. Comp. Sci. (2004) 44(6):1912–1928.
  • NEDELCHEVA V, GUT I: P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica (1994) 24(12):1151–1175.
  • MUGFORD CA, KEDDERIS GL: Sexdependent metabolism of xenobiotics. Drug Metab. Rev. (1998) 30(3):441–498.
  • OBACH RS: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and non specific binding to microsomes. Drug Metab. Dispos. (1999) 27:1350–1359.
  • LAVE T, DUPIN S, SCHMITT C et al.: Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J. Pharm. Sci. (1997) 86:584–590.
  • ITO K, IWATSUBO T, KANIMITSU S et al.: Prediction of pharmacokinetic alterations caused by drug—drug interactions: metabolic interaction in the liver. Pharmacol. Rev. (1998) 50:387–411.
  • SCHNEIDER G, COASSOLO P, LAVE T: Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. J. Med. Chem. (1999) 42:5072–5076.
  • EKINS S, OBACH RS: Three dimensionalquantitative structure activity relationship computational approaches of prediction of human in vitro intrinsic clearance. J. Pharmacol. Exp. Ther. (2000) 295:463–473.
  • DENNIS G Jr, SHERMAN BT, HOSACK DA et al.: DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. (2003) 4(5):P3.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.